12:00 AM
 | 
Sep 27, 2010
 |  BC Week In Review  |  Clinical News  |  Regulatory

Yondelis trabectedin regulatory update

The U.K.'s NICE issued a final appraisal determination (FAD) recommending against the use of Yondelis trabectedin in combination with pegylated liposomal doxorubicin hydrochloride (PLDH) to treat relapsed ovarian cancer - its approved indication. The recommendation is...

Read the full 158 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >